Rafael (NYSE:RFL) Releases Quarterly Earnings Results

Rafael (NYSE:RFL) released its quarterly earnings results on Thursday. The company reported ($0.08) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $0.18 million for the quarter. Rafael had a negative net margin of 2,846.60% and a negative return on equity of 37.27%.

Rafael Stock Up 18.7%

RFL opened at $2.11 on Friday. Rafael has a twelve month low of $1.12 and a twelve month high of $2.65. The company has a fifty day moving average of $1.35 and a 200-day moving average of $1.30. The stock has a market cap of $109.90 million, a PE ratio of -2.67 and a beta of 0.54.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Rafael

Several large investors have recently modified their holdings of RFL. Marshall Wace LLP acquired a new stake in shares of Rafael during the second quarter worth $50,000. Citadel Advisors LLC increased its position in shares of Rafael by 132.3% during the third quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock worth $99,000 after buying an additional 41,335 shares during the period. Renaissance Technologies LLC increased its position in shares of Rafael by 59.1% during the first quarter. Renaissance Technologies LLC now owns 89,138 shares of the company’s stock worth $111,000 after buying an additional 33,111 shares during the period. Cable Car Capital LP acquired a new stake in shares of Rafael during the second quarter worth $173,000. Finally, Geode Capital Management LLC increased its position in shares of Rafael by 25.4% during the fourth quarter. Geode Capital Management LLC now owns 445,866 shares of the company’s stock worth $526,000 after buying an additional 90,417 shares during the period. 11.30% of the stock is currently owned by institutional investors and hedge funds.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.